Credence Genomics provides convincing solutions to all your genomic and microbiological problems providing you with high quality, rapid products based on its unique in-house Next Generation Sequencing platform, at a competitive value and pricing. We are also available as a professional partner to facilitate your research and development projects with cutting-edge technology.
Having introduced Next Generation DNA sequencing based testing for the first time in the country, we provide novel, comprehensive, highly active solutions for a vast array of clinical conditions. These tests ares only the start point in a line of numerous innovative diagnostic / research tests and tools to arrive to the local and global market. With each service to disembark, Credence Genomics plans to provide address and unveil different aspects of genomics, incorporating all the power and capability of its in-house platform. This pioneering technology will provide the user with;
- Speed: Receive analyzed data back in a matter of 48 hours.
- Quality: Based on a Next Generation platform tests generate data with lowest error rates and highest sensitivity.
- Results: Biology matters and Credence Genomics is dedicated to serve its customers with a skilled team of well- trained scientists.
- Security: The Company treats each individual’s reports with maximum confidentiality, customer data is always in a secure, protected environment.
- Ease: Get in-depth analysis of all biological queries represented in most user-friendly manner.
- Affordability: Contact Credence Genomics to find out how surprisingly affordable Next Generation Sequencing is.
- Vast scope: Our test methods are applicable to all your requirements. We accept clinical, agricultural, food and beverage, pharmaceutical/ cosmetics, wastewater, soil, environmental as well as veterinary samples for testing/ research and diagnostics.
FungiFast by Credence Genomics is a rapid, accurate testing method specifically designed to identify fungal infections and contaminations in clinical as well as industrial environments. The test Detects and profiles the entire spectrum of known fungi present in the patient/ industrial samples while providing the Relative Abundances of each species of fungi present in the sample within 48 hours.
BactFast by Credence Genomics is a single test that allows detection of the entire spectrum of known bacteria present in clinical and industrial samples along with the Relative Abundance value of each species of bacteria. The test has efficiently replaced an entire cohort of conventional microbial and biochemical test methods and all of its drawbacks, generating highly transparent, accurate and more reliable data in rapid turn-around time (48 hours) with a minimum quantity of test sample.
Credence Tumor Hotspots
Credence Tumor Hotspots is a gene panel that tests for frequently mutated- Hotspot regions in 50 cancer causing genes. This test provides essential information on molecular basis of cancer (which differs from patient to patient even in same type of cancer) enabling the physicians to maximize the therapeutic outcome by effective diagnosis and management the patients health.
Credence Carrier Screening
Credence Carrier Screening is a gene panel that simultaneously tests 325 genes capable of causing 853 inherited diseases (diseases that are passed across generations). The test can be used for carrier screening (at any time; specially before marriage or embarking on a pregnancy) and diagnostic testing when a child is affected with a condition that can not be diagnosed with conventional tests.
Credence Newborn Screening
Credence New Born Screening is a gene panel that screens for genes responsible for causing Neonatal Metabolic Disorders including Phenylketonuria (PKU), Arylsulfatase A Deficiency,Maple Syrup Urine Disease. Biotinidase Deficiency and many more. The test can be used for Newborn Screening in general or for diagnostic testing when a child is affected with a suspected metabolic disorder.
Credence ColoRectal Screening
Credence ColoRectal is a gene panel that simultaneously screens 17 genes associated with hereditary colorectal cancer to assess a person’s risk of developing disease.The results of the test enable individuals as well as their healthcare professionals to develop an individualized medical management plan to significantly reduce the risk of cancer.
A gene panel test that tests 18 genes that are responsible for inherited predisposition to breast cancer.The results of the test enable individuals as well as their healthcare professionals to develop an individualized medical management plan to significantly reduce the risk of cancer.